Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature (4)
Nature Medicine (4)
Prostate Cancer and Prostatic Diseases (1)
Scientific Reports (1)
npj Precision Oncology (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (7)
Amendments and Corrections (3)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Diseases
Immunology
Medical research
Microbiology
Molecular biology
Molecular medicine
Oncology
Pathogenesis

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–11 of 11 results

Advanced filters: Author: Jennifer L. McQuade Clear advanced filters

Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma

Florentia Dimitriou
Xiaogang Wu
Bita Esmaeli
ResearchOpen Access19 Nov 2025
npj Precision Oncology

Volume: 9, P: 1-11
Neoadjuvant relatlimab and nivolumab in resectable melanoma

Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
ResearchOpen Access26 Oct 2022
Nature

Volume: 611, P: 155-160
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Treatment with neoadjuvant BRAF/MEK-targeted therapy results in higher rates of major pathological response in female compared with male patients with melanoma, and pharmacological inhibition of androgen receptor signalling improved the responses of male and female mice to BRAF/MEK-targeted therapy.

Christopher P. Vellano
Michael G. White
Jennifer A. Wargo
Research15 Jun 2022
Nature

Volume: 606, P: 797-803
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

In an interim analysis of a phase 1 trial of concurrent intrathecal and intravenous anti-PD1 delivery in patients with leptomeningeal disease and melanoma, treatment was feasible and well-tolerated with no dose-limiting toxicities.

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
ResearchOpen Access30 Mar 2023
Nature Medicine

Volume: 29, P: 898-905
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.

Miles C. Andrews
Connie P. M. Duong
Jennifer A. Wargo
Research08 Jul 2021
Nature Medicine

Volume: 27, P: 1432-1441
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Isabella C. Glitza Oliva
Sherise D. Ferguson
Michael A. Davies
Amendments and CorrectionsOpen Access22 Apr 2024
Nature Medicine

Volume: 30, P: 1787
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Rodabe N. Amaria
Michael Postow
Hussein A. Tawbi
Amendments and CorrectionsOpen Access09 Mar 2023
Nature

Volume: 615, P: E23
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Christopher P. Vellano
Michael G. White
Jennifer A. Wargo
Amendments and Corrections10 Jan 2023
Nature

Volume: 613, P: E3
Bodywide ecological interventions on cancer

Moving away from the traditional ‘tumor-centric’ view, the authors explore how systemic biology, as well as aging, co-morbidities and co-medications, all interact and influence cancer development and progression.

Guido Kroemer
Jennifer L. McQuade
Laurence Zitvogel
Reviews19 Jan 2023
Nature Medicine

Volume: 29, P: 59-74
Body composition as a determinant of the therapeutic index with androgen signaling inhibition

Andrew W. Hahn
Rebecca S. Tidwell
Christopher J. Logothetis
Research17 Jul 2024
Prostate Cancer and Prostatic Diseases

Volume: 28, P: 802-808
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study

Alessio Cortellini
Federico Bozzetti
Giampiero Porzio
ResearchOpen Access29 Jan 2020
Scientific Reports

Volume: 10, P: 1-9